



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/639,948	08/12/2003	Rajat Sethi	12695.6USD6	6989
23552	7590	04/06/2004	EXAMINER	
MERCHANT & GOULD PC P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			JONES, DWAYNE C	
			ART UNIT	PAPER NUMBER
			1614	
DATE MAILED: 04/06/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/639,948	Applicant(s) SETHI ET AL.	
	Examiner Dwayne C Jones	Art Unit 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>11/14/03</u> . | 6) <input type="checkbox"/> Other: ____ |

DETAILED ACTION

Status of Claims

1. Claims 1-8 are pending.
2. Claims 1-8 are rejected.

Information Disclosure Statement

3. The information disclosure statement filed on November 14, 2003 has been reviewed and considered, see enclosed copy of PTO FORM 1449.

Specification

4. The incorporation of essential material in the specification by reference to a foreign application or patent, or to a publication is improper. Applicant is required to amend the disclosure to include the material incorporated by reference. The amendment must be accompanied by an affidavit or declaration executed by the applicant, or a practitioner representing the applicant, stating that the amendatory material consists of the same material incorporated by reference in the referencing application. See *In re Hawkins*, 486 F.2d 569, 179 USPQ 157 (CCPA 1973); *In re Hawkins*, 486 F.2d 579, 179 USPQ 163 (CCPA 1973); and *In re Hawkins*, 486 F.2d 577, 179 USPQ 167 (CCPA 1973).
5. The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1, and 4-8 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the 3-acylated analogues of pyridoxal compounds of claims 2, 3, and pyridoxal-5-phosphate for the treatment of hypertrophy does not reasonably provide enablement for other types of 3-acylated analogues of pyridoxal. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims.

8. The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

(1) The nature of the invention:

The instant invention is directed to pyridoxal-containing compositions and methods of treating hypertrophy. The method comprises administering pyridoxal-containing compositions and methods of treating hypertrophy.

(2) The state of the prior art

The compounds of the inventions are pyridoxal-containing compositions. However, the prior art does not teach that all analogues of these pyridoxal-containing compositions to various types of analogues such as carbohydrates, DNA, glycerides, heteroaryl moieties, see WO 98/19690.

(3) The relative skill of those in the art

The relative skill of those in the art of pharmaceuticals is high.

(4) The predictability or unpredictability of the art

The unpredictability of the pharmaceutical art is very high. In fact, the courts have made a distinction between mechanical elements function the same in different circumstances, yielding predictable results, chemical and biological compounds often react unpredictably under different circumstances. Nationwide Chem. Corp. v. Wright, 458 F. Supp. 828, 839, 192 USPQ 95, 105(M.D. Fla. 1976); Aff'd 584 F.2d 714, 200 USPQ 257 (5th Cir. 1978); In re Fischer, 427 F.2d 833, 839, 166 USPQ 10, 24 (CCPA 1970). Thus, the physiological activity of a chemical or biological compound is

Art Unit: 1614

considered to be an unpredictable art. For example, in Ex Parte Sudilovsky, the Court held that Appellant's invention directed to a method for preventing or treating a disease known as tardive dyskinesia using an angiotensin converting enzyme inhibitor involved unpredictable art because it concerned the pharmaceutical activity of the compound. 21 USPQ2d 1702, 1704-5 (BDAI 1991); In re Fisher, 427 F.2d 1557, 1562, 29 USPQ, 22 (holding that the physiological activity of compositions of adrenocorticotrophic hormones was unpredictable art; In re Wright, 999 F.2d 1557, 1562, 29 USPQ d, 1570, 1513-14 (Fed. Cir. 1993) (holding that the physiological activity of RNA viruses was unpredictable art); Ex Parte Hitzeman, 9 USPQ2d 1821, 1823 (BDAI 1987); Ex Parte Singh, 17 USPQ2d 1714, 1715, 1716 (BPAI 1990). Likewise, the physiological or pharmaceutical activity of pyridoxal-containing compositions prior to filing of the instant invention was an unpredictable art.

(5) The breadth of the claims

The instant claims are very broad. For instance, claim 1 is directed to the plethora of compounds of the generic term of pyridoxal-containing compositions. The breadth of claims was a factor in Amgen v. Chugai Pharm. Co., 927 F.2d 1200, 18 USPQ2d (Fed. Cir.), cert. Denied, 502 U.S. 856 (1991). In the Amgen case, the patent claims were directed to DNA sequences that encoded amino acid sequences. Because a very small change in the amino acid sequence of a protein can result in a very large change in the structure-function activity of a protein and because the laws of protein

folding are in such a primitive state, predicting protein structure (and hence, activity) while knowing only the sequence of the protein is akin to predicting the weather for a date in the future.

(6) The amount of direction or guidance presented

The amount of guidance or direction needed to enable the invention is inversely related to the degree of predictability in the art. In re Fisher, 839, 166 USPQ 24. Thus, although a single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements, in cases involving unpredictable factors, such as most chemical reactions and physiological activity, more teaching or guidance is required. In re Fischer, 427 F.2d 839, 166 USPQ 24; Ex Parte Hitzeman, 9 USPQ 2d 1823. For example, the Federal Circuit determined that, given the unpredictability of the physiological activity of RNA viruses, a specification requires more than a general description and a single embodiment to provide an enabling disclosure for a method of protecting an organism against RNA viruses. In re Wright, 999 F.2d 1562-63, 27 USPQ2d 1575. In the instant case, given the unpredictability of the physiological or pharmaceutical activity of a pyridoxal-containing compositions to be effective in treating hypertrophy is insufficient for enablement other than compounds of the 3-acylated analogues of pyridoxal compounds of claims 2, 3, and pyridoxal-5-phosphate. The specification provides no guidance, in the way of enablement for pyridoxal-containing compositions other than the 3-acylated analogues of pyridoxal compounds of claims 2, 3, and pyridoxal-5-phosphate. In re Fisher, 427 F.2d 833, 166

Art Unit: 1614

USPQ 18 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 27 USPQ2d 1510 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991).

This is because it is not obvious from the disclosure of one species, what other species will work. In re Dreshfield, 110 F.2d 235, 45 USPQ 36 (CCPA 1940), gives this general rule: "It is well settled that in cases involving chemicals and chemical compounds, which differ radically in their properties it must appear in an applicant's specification either by the enumeration of a sufficient number of the members of a group or by other appropriate language, that the chemicals or chemical combinations included in the claims are capable of accomplishing the desired result." The article "Broader than the Disclosure in Chemical Cases," 31 J.P.O.S. 5, by Samuel S. Levin covers this subject in detail. A disclosure should contain representative examples, which provide reasonable assurance to one skilled in the art that the compounds fall within the scope of a claim will possess the alleged activity. See In re Riat et al. (CCPA 1964) 327 F2d 685, 140 USPQ 471; In re Barr et al. (CCPA 1971) 444 F 2d 349, 151 USPQ 724.

(7) The presence or absence of working examples

As stated above, the specification discloses pyridoxal-containing compositions that have the ability of treating hypertrophy. However, the instant specification only has enablement for analogous of pyridoxal-containing compositions of 3-acylated analogues of pyridoxal compounds of claims 2, 3, and pyridoxal-5-phosphate.

Art Unit: 1614

(8) The quantity of experimentation necessary

The quantity of experimentation needed to be performed by one skilled in the art is yet another factor involved in the determining whether "undue experimentation" is required to make and use the instant invention. "The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed." In re Wands, 858 F.2d 737, 8 USPQ2d 1404 (citing In re Angstadt, 537 F.2d 489, 502-04, 190 USPQ 214, 218 (CCPA 1976)). For these reasons, one of ordinary skill in the art would be burdened with undue "painstaking experimentation study" to determine all of the analogues or derivatives of pyridoxal-containing compositions that would be enabled in this specification.

Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

Art Unit: 1614

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

11. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

12. Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haque of U.S. Patent No. 6,339,085. Haque teaches treating hypertrophy in a mammal with the administration of the 3-acylated compounds of the formula in claim 1 concurrently with angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, a vasodilator, a diuretic, and mixtures thereof. Furthermore, Haque teaches enterally or parenterally administering these compounds as well as unit dosage forms of the compound disclosed in claim 1. The 3-acylated pyridoxal compounds as disclosed in claim 1 of Haque has a larger genus than the 3-acylated pyridoxal compounds of the instant invention. However, it would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the reference, including those of the claims,

because an ordinary artisan would have the reasonable expectation that any of the species would have similar properties and, thus, the same use as the genus as a whole.

13. Applicant has provided evidence in this file showing that the invention was owned by, or subject to an obligation of assignment to, the same entity as Haque of U.S.

Patent No. 6,339,085 at the time this invention was made. Accordingly, Haque of U.S. Patent No. 6,339,085 is disqualified as prior art through 35 U.S.C. 102(f) or (g) in any rejection under 35 U.S.C. 103(a) in this application. However, this applied art additionally qualifies as prior art under another subsection of 35 U.S.C. 102 and accordingly is not disqualified as prior art under 35 U.S.C. 103(a).

14. Applicant may overcome the applied art either by a showing under 37 CFR 1.132 that the invention disclosed therein was derived from the invention of this application, and is therefore, not the invention "by another," or by antedating the applied art under 37 CFR 1.131.

15. Claims 1-8 are rejected under 35 U.S.C. 103(a) as being obvious over Haque of U.S. Patent No. 6,339,085.

16. The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention "by another"; (2) a showing of a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed

in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). For applications filed on or after November 29, 1999, this rejection might also be overcome by showing that the subject matter of the reference and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person. See MPEP § 706.02(I)(1) and § 706.02(I)(2).

17. Haque teaches treating hypertrophy in a mammal with the administration of the 3-acylated compounds of the formula in claim 1 concurrently with angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, a vasodilator, a diuretic, and mixtures thereof. Furthermore, Haque teaches enterally or parenterally administering these compounds as well as unit dosage forms of the compound disclosed in claim 1. The 3-acylated pyridoxal compounds as disclosed in claim 1 of Haque has a larger genus than the 3-acylated pyridoxal compounds of the instant invention. However, it would have been obvious to one having ordinary skill in the art at the time of the invention to select any of the species of the genus taught by the reference, including those of the claims, because an ordinary artisan would have the reasonable expectation that any of the species would have similar properties and, thus, the same use as the genus as a whole.

18. Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith et al. of WO 98/19690 in view of DiPiro. Smith et al. teach that one of the causes of the microvascular events leading to ischemia in the medial temporal lobe is a moderate deficiency in vitamin B₁₂ and folate, which leads to elevated homocysteine levels in the plasma, because vitamin B₁₂ and folate are required cofactors in the conversion of homocysteine to methione. Homocysteine can have a toxic effect on the blood vessels that initiates the pathological cascade process leading to changes in the microvasculature, (see page 2, lines 5-12 and 31-36). Smith et al. teach of the administration angiotensin-converting enzyme (ACE) inhibitors, such as enalapril, to treat high blood pressure, (see page 3). Smith et al. also teach that the administration of ACE-inhibitors and angiotensin II antagonists are known to reduce the damage to the endothelium and to the elastic laminae in arterioles caused by homocysteine. In addition, Smith et al. disclose that ACE-inhibitors are known to potentiate the response of the endothelium to agonists that increase the release of endothelium-derived relaxing factors, such as nitric oxide, (see page 4, lines 16-33). Smith et al. specifically, teach of the concurrent administration of vitamin B₆ or B₁₂ in combination with an ACE inhibitor or an angiotensin II antagonist in order to modify the deleterious effects of homocysteine on the vasculature, (see page 5, lines 7-20). Smith et al. also disclose the term occlusive vascular disease encompasses inter alia, stroke and TIA, (see page 6, lines 16-19). DiPiro teach congestive heart failure can be the result of many causes, inter alia, hypertension and vasoconstriction, (see pages 115-118). DiPiro also disclose of the pathophysiology of congestive heart failure is the result of many contributing factors,

Art Unit: 1614

namely pressure overload, volume overload, loss of muscles, decreased contractility and disturbances in filling. This decrease may further be the consequence of hypertrophy of the ventricle that may produce dramatic changes in compliance. DiPiro also disclose that hypertension, coronary artery disease, and restricted ventricular compliance may be brought about by scar formation after an infarct or even excessive hypertrophy, (see page 115). Accordingly, the skilled artisan would have been motivated to use the teachings of Smith et al. to treat a variety of ailments that are related to occlusive vascular disease, such as the reduced blood flows in patients with various heart abnormalities that relate to congestive heart failure, namely hypertrophy. It is well known in the art that vitamin B₆ is embraced by pyridoxine and related compounds, such as pyridoxal and pyridoxamine, (see Stedman's Medical Dictionary, 25th Edition, page 1726). For these reasons, it would have been obvious to one having ordinary skill in the art to employ these compositions especially since it is shown in the prior art that these compositions, namely Vitamin B₆ and its related compounds such as pyridoxamine and pyridoxal 5'-phosphate and other structurally related compounds of pyridoxine, as well as ACE inhibitors and angiotensin II antagonists are known to treat microvascular events that lead to the treatment of hypertrophy.

19. Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Smith et al. of WO 98/19690 in view of Lobel of U.S. Patent No. 3,282,778. Smith et al. teach that one of the causes of the microvascular events leading to ischemia in the medial temporal lobe is a moderate deficiency in vitamin B₁₂ and folate, which leads to elevated homocysteine levels in the plasma, because vitamin B₁₂ and folate are

Art Unit: 1614

required cofactors in the conversion of homocysteine to methione. Homocysteine can have a toxic effect on the blood vessels that initiates the pathological cascade process leading to changes in the microvasculature, (see page 2, lines 5-12 and 31-36). Smith et al. teach of the administration angiotensin-converting enzyme (ACE) inhibitors, such as enalapril, to treat high blood pressure, (see page 3). Smith et al. also teach that the administration of ACE-inhibitors and angiotensin II antagonists are known to reduce the damage to the endothelium and to the elastic laminae in arterioles caused by homocysteine. In addition, Smith et al. disclose that ACE-inhibitors are known to potentiate the response of the endothelium to agonists that increase the release of endothelium-derived relaxing factors, such as nitric oxide, (see page 4, lines 16-33). Smith et al. specifically, teach of the concurrent administration of vitamin B₆ or B₁₂ in combination with an ACE inhibitor or an angiotensin II antagonist in order to modify the deleterious effects of homocysteine on the vasculature, (see page 5, lines 7-20). Smith et al. also disclose the term occlusive vascular disease encompasses inter alia, stroke and TIA, (see page 6, lines 16-19). DiPiro teach congestive heart failure can be the result of many causes, inter alia, hypertension and vasoconstriction, (see pages 115-118). DiPiro also disclose of the pathophysiology of congestive heart failure is the result of many contributing factors, namely pressure overload, volume overload, loss of muscles, decreased contractility and disturbances in filling. This decrease may further be the consequence of hypertrophy of the ventricle that may produce dramatic changes in compliance. DiPiro also disclose that hypertension, coronary artery disease, and restricted ventricular compliance may be brought about by scar formation after an infarct

Art Unit: 1614

or even excessive hypertrophy, (see page 115). Accordingly, the skilled artisan would have been motivated to use the teachings of Smith et al. to treat a variety of ailments that are related to occlusive vascular disease, such as the reduced blood flows in patients with various heart abnormalities that relate to congestive heart failure, namely hypertrophy. It is well known in the art that vitamin B₆ is embraced by pyridoxine and related compounds, such as pyridoxal and pyridoxamine, (see Stedman's Medical Dictionary, 25th Edition, page 1726). In addition, teach of pharmaceutical compositions that contain cardiovascular drugs as well as various compounds of the pyridoxine family, inter alia, pyridoxamine, pyridoxal, pyridoxal phosphate complex and pyridoxamine phosphate complex, (see column 1). Accordingly, it would have been obvious to one having ordinary skill in the art to utilize this old pharmaceutical composition for a new intended use. For these reasons, it would have been obvious to one having ordinary skill in the art to employ these compositions especially since it is shown in the prior art that these compositions, namely Vitamin B₆ and its related compounds such as pyridoxamine and pyridoxal 5'-phosphate and other structurally related compounds of pyridoxine, as well as ACE inhibitors and angiotensin II antagonists are known to treat microvascular events that lead to the treatment of hypertrophy.

Obviousness-type Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA

Art Unit: 1614

1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

20. Claims 1 and 3-8 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, and 46-48 of U.S. Patent No. 6,339,085. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant invention and U.S. Patent No. 6,339,085 teach treating hypertrophy in a mammal with the administration of the 3-acylated compounds of the formula in claim 1 concurrently with angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, a vasodilator, a diuretic, and mixtures thereof. Furthermore, the instant invention and U.S. Patent No. 6,339,085 both teach enterally or parenterally administering these compounds as well as unit dosage forms of the compound disclosed in claim 1.

21. Claims 1 and 3-8 are directed to an invention not patentably distinct from claims 1, and 46-48 of commonly assigned U.S. Patent No. 6,339,085. Specifically, both the instant invention and U.S. Patent No. 6,339,085 teach of treating hypertrophy in a mammal with the administration of the 3-acylated compounds of the formula in claim 1 concurrently with angiotensin converting enzyme inhibitor, an angiotensin II receptor antagonist, and a calcium channel blocker, a vasodilator, a diuretic, and mixtures

Art Unit: 1614

thereof. Furthermore, the instant invention and U.S. Patent No. 6,339,085 both teach enterally or parenterally administering these compounds as well as unit dosage forms of the compound disclosed in claim 1.

22. The U.S. Patent and Trademark Office normally will not institute an interference between applications or a patent and an application of common ownership (see MPEP § 2302). Commonly assigned U.S. Patent No. 6,339,085, discussed above, would form the basis for a rejection of the noted claims under 35 U.S.C. 103(a) if the commonly assigned case qualifies as prior art under 35 U.S.C. 102(f) or (g) and the conflicting inventions were not commonly owned at the time the invention in this application was made. In order for the examiner to resolve this issue, the assignee is required under 35 U.S.C. 103(c) and 37 CFR 1.78(c) to either show that the conflicting inventions were commonly owned at the time the invention in this application was made or to name the prior inventor of the conflicting subject matter. Failure to comply with this requirement will result in a holding of abandonment of the application.

23. A showing that the inventions were commonly owned at the time the invention in this application was made will preclude a rejection under 35 U.S.C. 103(a) based upon the commonly assigned case as a reference under 35 U.S.C. 102(f) or (g), or 35 U.S.C. 102(e) for applications filed on or after November 29, 1999.

24. Claims 1, 2, and 4-8 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 and 40-42 of copending Application No. 09/863,093. Although the conflicting claims are not identical, they are not patentably distinct from each other because both the instant

invention and copending Application No. 09/863,093 teach of treating hypertrophy with the concurrent administration of 3-acylated pyridoxal compounds of claim 1 along with additional cardiovascular compounds *inter alia*, ACE inhibitors and angiotensin II antagonists and calcium channel blockers.

25. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (571) 272-0578. The examiner can normally be reached on Mondays, Tuesdays, Thursday, and Fridays from 8:30 am to 6:00 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, may be reached at (571) 272-0584. The official fax No. for correspondence is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov> Should

Art Unit: 1614

you have any questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll free).


DWAYNE JONES
PRIMARY EXAMINER

Tech. Ctr. 1614
April 2, 2004